There’s new hope for those in the early stages of Alzheimer’s. A recent study found that an experimental drug from pharmaceutical company Eli Lilly can slow the progression of Alzheimer’s by about 35%. However, the new drug also comes with an increased risk of side effects.
Host Celeste Headlee discusses the benefits and the risks with STAT’s Adam Feuerstein.
This article was originally published on WBUR.org.
Copyright 2023 NPR. To see more, visit https://www.npr.org.
